Mechelen (Belgium), September 12th, 2014 – Biocartis, an innovative molecular diagnostics company, announced today that it has officially launched its flagship molecular diagnostics system Idylla™. Idylla™’s unrivaled ease of use, access on-demand design, speed and superior sensitivity are unprecedented in the field of molecular diagnostics. Together with Idylla™, Biocartis also released its first oncology assay, the Idylla™ BRAF Mutation Test. Both Idylla™ and the Idylla™ BRAF Mutation Test have obtained CE-IVD(1) marking.
“Molecular testing plays a key role in the treatment decision process. It allows doctors to select specifically designed therapies based on the genetic profile of their patient”, said Rudi Pauwels, CEO & Executive Chairman of Biocartis. “Traditionally, molecular diagnostics involves a series of specialized, labor-intensive and time-consuming steps. As a result, most labs do not perform these tests in-house, but send them to specialized labs where they are batched, often delaying treatment decisions.”
Idylla™, Biocartis’ fully automated, real-time PCR system, sets the standard for a novel way of molecular testing. Idylla™’s access on-demand design allows clinicians to initiate a new test at any given time, without the need for batching or for trained operators. The system’s short turnaround time – between 35 and 120 minutes – enables laboratories to report same-day results, significantly speeding up the treatment decision process. Furthermore, Idylla™’s multiplex capability offers the possibility to detect up to 30 molecular targets(2) simultaneously in the same sample, making the system very well suited for more complex assays.
The BRAF Mutation Test is Idylla™’s first oncology test and is designed to determine the most appropriate treatment for a specific type of skin cancer. The assay can detect mutations directly from FFPE(3) tissue slices in about 90 minutes. This direct processing of FPE tissue slices is unique for BRAF testing. The excellent analytical sensitivity of the Idylla™ BRAF Mutation Test was demonstrated during clinical performance studies. Rudi Pauwels added: “Biocartis has the crucial expertise in house to bring a whole new generation of diagnostic tests for oncology and infectious diseases to the market. Furthermore, we are also working with Janssen Pharmaceutica and Abbott Molecular to develop a range of diagnostic tests in other disease areas.”
“We are convinced that Idylla™ will completely transform the day-to-day practice in molecular labs, making molecular testing more straightforward than ever imagined. This will significantly speed up the diagnostic process and will enable doctors to make therapy decisions in a much shorter time frame. Ultimately, patients will receive a personalized therapy faster, ultimately improving treatment outcomes”, stated Rudi Pauwels.
---end---
About personalized medicine & molecular diagnostics
Every person has a unique genetic profile. Understanding and leveraging the molecular mechanisms underlying diseases empowers doctors to shift away from the one-drug-fits-all paradigm and tailor a treatment to the genetic profile of their patient, also known as ‘personalized medicine’. Specific molecular diagnostics tests can, for instance, aid a doctor in the selection of the appropriate therapy for a melanoma patient whose tumor carries a specific genetic mutation. Eventually, this makes treatments more effective, improves outcomes and ultimately reduces healthcare costs. However, in order to be truly sustainable and beneficial, molecular information needs to be gathered quickly and easily, at the point of need. Today, this is not the case. Most hospitals do not perform molecular tests in-house, but send the test samples out to specialized labs where they are processed in batches, on multiple instruments and operated by highly trained personnel. This time-consuming and labor-intensive process delays treatment decisions which are often crucial to save patients’ lives.
About Idylla™ (www.idylla.com)
Biocartis has developed a miniaturized, fully automated molecular system that integrates all molecular diagnostic steps in one easy-to-use system. Idylla™ offers clinicians fast and easy access to molecular diagnostics information, anywhere and anytime. It can be used for any human clinical sample type and covers the entire process from sample to result in a time frame of 35 to 120 minutes. Idylla™ enables clinical laboratories to perform a broad range of applications in oncology, infectious diseases and beyond. Idylla™ and the system’s first assay, the Idylla™ BRAF Mutation Test, have obtained CE-IVD marking.
High resolution images of Idylla™, Biocartis’ flagship molecular diagnostics system, and Rudi Pauwels, CEO & Executive chairman Biocartis, available on request: idebecker@biocartis.com
About BRAF
About 50% of melanoma patients harbor mutations in the BRAF oncogene. In more than 90% of the cases, BRAF mutations are located in the BRAF V600 codon (V600E and V600K). Several therapies that treat cancers associated with BRAF mutations have been developed, showing response rates in up to half of metastatic melanomas. Tumor mutation status is usually assessed starting from formalin-fixed paraffin-embedded (FFPE) tumor tissue material. Currently the process for detecting BRAF mutations is labor-intensive, requiring multiple steps. Most labs do not perform these tests in-house, but send them to specialized laboratories, where samples are batched such that it often takes weeks before results are available.
About Biocartis (www.biocartis.com)
Biocartis strives to transform the global diagnostics market by providing instant access to personalized medicine for patients worldwide. The company develops fully integrated and broadly applicable molecular diagnostic solutions that can be used in a wide variety of healthcare settings to provide rapid, high-quality care to patients. Biocartis is working with Janssen Pharmaceutica and Abbott Molecular to develop a range of diagnostic tests in different disease areas. Biocartis has set up in-house commercial scale manufacturing capabilities at its premises in Mechelen (near Brussels). The Idylla™ system and its first oncology assay, the Idylla ™ BRAF Mutation Test, have obtained CE-IVD marking.
Media Contact:
Imke Debecker, Communications Manager Biocartis
Phone: +32 15 632 896
+32 497 364 507
E-mail: idebecker@biocartis.com
Spokesperson:
Rudi Pauwels, CEO & Executive Chairman, Biocartis
Help employers find you! Check out all the jobs and post your resume.
